pSivida Corp. - NASDAQ: PSDV

[Caio80]

entrato ieri in chiusura, vai con lo swing, tg min +20%:

 

[Caio80]

ed oggi passiamo alla cassa

Nicox and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma Paris Stock Exchange:COX

Press Release
Nicox and pSivida Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma

Focus will be on Combining Nicox's New Nitric Oxide Donating Compounds with pSivida's Bioerodible Sustained Release Delivery Technology


October 10, 2017 - release at 7:30 am CET
Sophia Antipolis, France and Watertown, Mass, United States

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, and pSivida Corp, (NASDAQSDV) (ASXVA), a leader in the development of sustained release drug products and technologies, today announced their entry into a collaboration agreement to explore the potential of combining Nicox's nitric oxide (NO)-donating compounds with pSivida's bioerodible sustained release drug delivery system, to develop a sustained release drug to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Nicox and pSivida will collaborate on the selection of NO-donating product candidates from Nicox's research portfolio to combine with pSivida's sustained release drug technology. pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums by Nicox. The companies may then elect to proceed with further development, including more detailed non-clinical studies to generate pre-clinical data, and the evaluation of further compounds under the collaboration. Nicox would make additional payments for any incremental development activities for each implant formulation product candidate selected by Nicox to progress in development. New intellectual property from the collaboration relating to the drug-device combination will be jointly owned. Nicox and pSivida will negotiate a separate license agreement for any product candidate that the two companies wish to further develop and potentially commercialize as a result of this collaboration. Expected payments from Nicox associated with this agreement are not considered material to Nicox's financial statements at this time.

Michael Bergamini, Executive Vice President and Chief Scientific Officer, stated "We have strong pre-clinical data demonstrating the IOP lowering effect of our novel stand-alone NO donors, such as our lead NCX 667, and believe that their profile makes them product candidates for potential sustained release delivery. The bioerodible technology in development by pSivida, combined with their proven success in developing sustained delivery devices for the eye, puts them at the forefront of this exciting area."

"Nicox's NO-donating research platform has been validated in both pre-clinical and human studies for the reduction of IOP." commented Nancy Lurker, President & CEO of pSivida, "Combining this novel approach to IOP lowering with our bioerodible, sustained delivery device could offer a unique therapy alternative or adjunct to existing therapies to lower IOP in order to help prevent the development and progression of glaucoma."

 

[papi67]

entrato ieri in chiusura, vai con lo swing, tg min +20%:

in pre si sta sgonfiando, speriamo regga 1.40

 

[Implacabile]

Mi pare alquanto strano che pSivida concluda un accordo sul glaucoma e pochi giorni dopo sigli con Nicox un altro accordo sul glaucoma.


September 26, 2017

pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs




WATERTOWN, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQSDV) (ASXVA), a leader in the development of sustained release drug products and technologies, has signed an agreement with a major global pharmaceutical company to develop two glaucoma drugs with pSivida's proprietary sustained release technology. This agreement builds upon the positive results seen in pre-clinical studies demonstrating extended release of drug for up to six months utilizing pSivida's proprietary technology. The terms of the partnership includes upfront payments to pSivida of $750,000 for initial development and potential additional payments totaling $200,000 if all subsequent development activities are conducted.


"A key focus for pSivida during 2017 is to expand the number of development collaboration agreements with other drug manufacturers and this is the second such agreement during 2017," said Nancy Lurker, President & CEO. "This agreement extends the strong working relationship between the two organizations. Glaucoma is one of the major causes of blindness and many patients are not compliant with administering the commonly prescribed treatment of daily drops. Our proprietary sustained release technology, combined with glaucoma drugs, has the potential to provide new dosing options for patients."

 

[Caio80]

riproviamoci oggi

 

[Caio80]

questa ha brekkato, ha molto spazio per salire

 

[davicerr]

Se romper 1,30 ci potrebbe essere un buon run intraday

 

[martins.c]

ocio a questa... nda fast track in vista...

 

[martins.c]

1.11 ocio

 

[martins.c]

1.13 pianino pianino

 

[luxM3]

ocio a questa... nda fast track in vista...

ti seguo